4
MARKET OVERVIEW
Unlock growth by navigating oligo CDMO demand, precision medicine focus, and CRISPR-Cas9 opportunities.
45
4.2.1.1
GROWING DEMAND FOR PRE-CLINICAL-TO-COMMERCIAL OLIGO CDMOS
4.2.1.2
INCREASE IN CDMO PARTNERSHIPS FOR SCALABILITY
4.2.1.3
INCREASING FOCUS ON PRECISION/PERSONALIZED MEDICINE
4.2.2.1
COMPLEXITIES ASSOCIATED WITH THERAPEUTIC OLIGONUCLEOTIDE MANUFACTURING
4.2.3.1
INCREASING USE OF OLIGOS IN CRISPR-CAS9 APPLICATIONS
4.2.3.2
EXPANSION OF OLIGONUCLEOTIDE THERAPEUTICS INTO CARDIOMETABOLIC AND COMMON CHRONIC DISEASES
4.2.4.1
LACK OF SUSTAINABLE SUPPLY CHAIN
4.2.4.2
LIMITED SCALABILITY OF GMP OLIGONUCLEOTIDE SYNTHESIS
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Navigate industry shifts with insights on competitive forces and global biotech and healthcare trends.
53
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
INTENSITY OF COMPETITIVE RIVALRY
5.1.2
BARGAINING POWER OF SUPPLIERS
5.1.3
BARGAINING POWER OF BUYERS
5.1.4
THREAT OF SUBSTITUTES
5.1.5
THREAT OF NEW ENTRANTS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4
TRENDS IN GLOBAL BIOTECH INDUSTRY
5.4.1
ROLE OF PLAYERS IN ECOSYSTEM
5.5
KEY CONFERENCES & EVENTS, 2026–2027
5.6
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.7
INVESTMENT & FUNDING SCENARIO
5.8
IMPACT OF 2025 US TARIFF ON OLIGONUCLEOTIDE CDMO MARKET
5.8.3
PRICE IMPACT ANALYSIS
5.8.4
IMPACT ON COUNTRY/REGION
5.8.5
IMPACT ON END-USE INDUSTRIES
5.8.5.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
5.8.5.2
DIAGNOSTIC COMPANIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations revolutionize oligonucleotide synthesis, enhancing efficiency and market readiness.
71
6.1.1.1
PROCESS TECHNOLOGIES
6.1.1.1.1
SOLID-PHASE SYNTHESIS
6.1.1.1.2
LIQUID-PHASE SYNTHESIS
6.1.1.1.3
ENZYMATIC PHASE SYNTHESIS
6.1.1.2
PURIFICATION, ANALYSIS, AND QUALITY CONTROL TECHNOLOGIES
6.1.1.2.1
AFFINITY CHROMATOGRAPHY
6.1.1.2.2
TANGENTIAL FLOW FILTRATION (TFF) & ULTRAFILTRATION
6.1.2
COMPLEMENTARY TECHNOLOGIES
6.1.2.1
POLYMERASE CHAIN REACTION (PCR)
6.1.2.2
NEXT-GENERATION SEQUENCING (NGS)
6.1.2.3
MICROARRAY TECHNOLOGY/HYBRIDIZATION-BASED ASSAYS
6.1.3
ADJACENT TECHNOLOGIES
6.1.3.1
GALNAC CONJUGATION/ANTIBODY–OLIGONUCLEOTIDE CONJUGATION
6.1.3.2
LIPID NANOPARTICLE (LNP) ENCAPSULATION
6.4
IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
6.4.1
TOP USE CASES AND MARKET POTENTIAL
6.4.2
BEST PRACTICES IN AI-ENABLED OLIGONUCLEOTIDE CDMO WORKFLOWS
6.4.3
CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET
6.4.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.4.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
Navigate global sustainability with insights on regional regulations, compliance, and eco-standards impact.
80
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2.4
REST OF THE WORLD
7.2
SUSTAINABILITY INITIATIVES
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock strategic insights into stakeholder influence and unmet needs driving purchase decisions.
88
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2
KEY BUYING CRITERIA, BY END USER
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 37 Data Tables
92
9.2
CONTRACT MANUFACTURING
9.2.1.1
ADVANCING OLIGONUCLEOTIDE THERAPIES AND DEMAND FOR RELIABLE COMMERCIAL-SCALE GMP SUPPLY ARE DRIVING GROWTH IN COMMERCIAL-STAGE SERVICES
9.2.2.1
ADVANCING CLINICAL PIPELINES AND DEMAND FOR SPECIALIZED SCALABLE MANUFACTURING ARE DRIVING GROWTH IN CLINICAL-STAGE SERVICES
9.3.1
INCREASINGLY COMPLEX OLIGONUCLEOTIDE PIPELINES AND DEMAND FOR OPTIMIZED CLINICAL MANUFACTURING PROCESSES ARE DRIVING CONTRACT DEVELOPMENT GROWTH
9.4.1
INCREASING MOLECULAR COMPLEXITY AND DEMAND FOR INTEGRATED ANALYTICAL AND DRUG-PRODUCT SUPPORT ARE DRIVING GROWTH IN OTHER SERVICES
10
OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
111
10.2
THERAPEUTIC APPLICATIONS
10.2.1
EXPANDING THERAPEUTIC APPLICATIONS AND ADVANCING OLIGONUCLEOTIDE PIPELINES ARE DRIVING DEMAND FOR SPECIALIZED CDMO SERVICES.
10.3
RESEARCH APPLICATIONS
10.3.1
EXPANDING GENOMICS, SEQUENCING, CRISPR RESEARCH, AND OUTSOURCED CUSTOM SYNTHESIS DRIVE GROWTH
10.4
DIAGNOSTIC APPLICATIONS
10.4.1
EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION ONCOLOGY DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE MANUFACTURING
11
OLIGONUCLEOTIDE CDMO MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
123
11.2
ANTISENSE OLIGONUCLEOTIDE (ASO)
11.2.1
ADVANCING ASO PIPELINES AND INCREASING DEMAND FOR SCALABLE GMP MANUFACTURING ARE DRIVING GROWTH
11.3
SMALL INTERFERING RNA (SIRNA)
11.3.1
EXPANDING SIRNA PIPELINES AND INCREASING DEMAND FOR SPECIALIZED GMP MANUFACTURING ARE DRIVING GROWTH IN THE MARKET.
11.4
OTHER OLIGONUCLEOTIDES
11.4.1
EXPANDING CRISPR AND TARGETED APTAMER APPLICATIONS DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE CDMO CAPABILITIES
12
OLIGONUCLEOTIDE CDMO MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
135
12.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.2.1
EXPANDING NUCLEIC ACID PIPELINES AND INCREASING OUTSOURCING DRIVE PHARMACEUTICAL AND BIOTECHNOLOGY DEMAND FOR CDMO SERVICES
12.3
DIAGNOSTIC COMPANIES
12.3.1
RISING MOLECULAR TESTING AND DEMAND FOR COMPLIANT CUSTOM OLIGOS DRIVE DIAGNOSTIC OUTSOURCING
13
OLIGONUCLEOTIDE CDMO MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 147 Data Tables.
147
13.2.1.1
EXPANDING DOMESTIC GMP CAPACITY AND INCREASING OUTSOURCING ARE DRIVING US OLIGONUCLEOTIDE CDMO GROWTH.
13.2.2.1
INTEGRATED NORTH AMERICAN MANUFACTURING NETWORKS AND GROWING OUTSOURCING DEMAND ARE SUPPORTING CANADA’S OLIGONUCLEOTIDE CDMO MARKET
13.3.1.1
EXPANDING GMP CAPACITY AND INTEGRATED OLIGONUCLEOTIDE PARTNERSHIPS ARE DRIVING GERMANY’S MARKET GROWTH
13.3.2.1
STRENGTHENING DOMESTIC NUCLEIC-ACID INFRASTRUCTURE AND GROWING OUTSOURCING DEMAND ARE DRIVING UK OLIGONUCLEOTIDE CDMO GROWTH
13.3.3.1
STRENGTHENING NUCLEIC-ACID CAPABILITIES AND GROWING OUTSOURCING DEMAND ARE DRIVING FRANCE’S OLIGONUCLEOTIDE CDMO MARKET
13.3.4.1
SPECIALIZED OLIGONUCLEOTIDE INFRASTRUCTURE AND GROWING DEMAND FOR INTEGRATED DEVELOPMENT SERVICES ARE SUPPORTING ITALY’S MARKET GROWTH
13.3.5.1
EXPANDING DOMESTIC MANUFACTURING INFRASTRUCTURE AND INSTITUTIONAL SUPPORT FOR THERAPEUTIC OLIGONUCLEOTIDES ARE DRIVING SPAIN’S MARKET GROWTH
13.4.1.1
EXPANDING INTEGRATED MANUFACTURING CAPACITY AND STRENGTHENING DOMESTIC OLIGONUCLEOTIDE SUPPLY CHAINS ARE DRIVING CHINA’S MARKET GROWTH
13.4.2.1
ADVANCED MANUFACTURING CAPABILITIES AND RISING DEMAND FOR COMPLEX OLIGONUCLEOTIDE THERAPEUTICS ARE DRIVING JAPAN’S MARKET GROWTH
13.4.3.1
EXPANDING GMP INFRASTRUCTURE AND GLOBAL OUTSOURCING ARE DRIVING INDIA’S OLIGONUCLEOTIDE CDMO MARKET
13.4.4.1
EXPANDING DOMESTIC MANUFACTURING AND GROWING BIOPHARMACEUTICAL OUTSOURCING ARE SUPPORTING AUSTRALIA’S OLIGONUCLEOTIDE CDMO MARKET
13.4.5.1
SYNTHETIC BIOLOGY, ORGANOID-BASED SCREENING, AND AI-ENABLED DISCOVERY TO SUPPORT MARKET GROWTH
13.4.6
REST OF ASIA PACIFIC
13.5.1.1
INFECTIOUS-DISEASE RESEARCH, SHARED PROTEIN-PRODUCTION INFRASTRUCTURE, AND VACCINE INNOVATION TO DRIVE MARKET
13.5.2.1
NEARSHORING AND EXPANDING REGIONAL MANUFACTURING CAPABILITIES ARE SUPPORTING MEXICO’S OLIGONUCLEOTIDE CDMO MARKET
13.5.3
REST OF LATIN AMERICA
13.6.1.1.1
BIOTECHNOLOGY LOCALIZATION AND EXPANDING GENOMIC MEDICINE CAPABILITIES ARE DRIVING SAUDI ARABIA’S OLIGONUCLEOTIDE CDMO MARKET
13.6.1.2.1
GROWING BIOPHARMACEUTICAL ACTIVITY AND NEED FOR LOCALIZED ADVANCED-THERAPY MANUFACTURING ARE CREATING OPPORTUNITIES FOR UAE’S OLIGONUCLEOTIDE CDMO SERVICES
13.6.1.3
REST OF GCC COUNTRIES
13.6.2
REST OF MIDDLE EAST
13.7.1
GROWING GENOMICS ACTIVITY AND LIMITED LOCAL MANUFACTURING CAPACITY ARE CREATING OPPORTUNITIES FOR OLIGONUCLEOTIDE CDMO SERVICES ACROSS AFRICA
14
COMPETITIVE LANDSCAPE
Navigate the oligonucleotide CDMO market with insights on key strategies and emerging leaders.
210
14.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1
KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023–2026
14.4
MARKET SHARE ANALYSIS
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE CDMO MARKET), 2025
14.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
14.6.1
PROGRESSIVE COMPANIES
14.6.2
RESPONSIVE COMPANIES
14.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
14.7
COMPETITIVE SCENARIO
14.8
BRAND/PRODUCT COMPARATIVE ANALYSIS
14.9
COMPANY VALUATION AND FINANCIAL METRICS
14.9.1
COMPANY VALUATION AND FINANCIAL METRICS FOR OLIGONUCLEOTIDE CDMO PLAYERS
15
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
232
15.1.1.1
BUSINESS OVERVIEW
15.1.1.2
SERVICES OFFERED
15.1.1.3
RECENT DEVELOPMENTS
15.1.1.3.1
PRODUCT/SERVICE LAUNCHES
15.1.1.4.2
STRATEGIC CHOICES
15.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
15.1.2
THERMO FISHER SCIENTIFIC INC.
15.1.3
AGILENT TECHNOLOGIES, INC.
15.1.5
MARAVAI LIFESCIENCES
15.1.7
EUROFINS SCIENTIFIC
15.1.8
DANAHER CORPORATION
15.1.10
SYNGENE INTERNATIONAL LIMITED
15.1.12
AJINOMOTO CO., INC.
15.1.14
KANEKA CORPORATION
15.1.15
POLYPEPTIDE GROUP
15.1.16
AURIGENE PHARMACEUTICAL SERVICES LTD.
15.1.18
NIPPON SHOKUBAI CO., LTD.
15.1.19
LGC BIOSEARCH TECHNOLOGIES
15.2.3
BIO-SYNTHESIS, INC.
15.2.5
SYNOLIGO BIOTECHNOLOGIES, INC.
15.2.6
HONGENE BIOTECH CORPORATION
16
RESEARCH METHODOLOGY
294
16.1.1.1
KEY DATA FROM SECONDARY SOURCES
16.1.2.1
KEY DATA FROM PRIMARY SOURCES
16.1.2.2
KEY PRIMARY PARTICIPANTS
16.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
16.1.2.4
KEY INDUSTRY INSIGHTS
16.2
MARKET SIZE ESTIMATION
16.2.1
GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025
16.2.2
SEGMENTAL MARKET SIZE ESTIMATION
16.3
MARKET GROWTH RATE PROJECTIONS
16.6
RESEARCH ASSUMPTIONS
16.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3
CUSTOMIZATION OPTIONS
TABLE 1
OLIGONUCLEOTIDE CDMO MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
TABLE 3
OLIGONUCLEOTIDE CDMO MARKET: PORTER’S FIVE FORCES
TABLE 4
OLIGONUCLEOTIDE CDMO MARKET: ROLE OF PLAYERS IN ECOSYSTEM
TABLE 5
OLIGONUCLEOTIDE CDMO MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–JUNE 2027
TABLE 6
RECIPROCAL TARIFF RATES ADJUSTED BY US
TABLE 7
CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET
TABLE 8
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES IN OLIGONUCLEOTIDE CDMO MARKET
TABLE 9
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
TABLE 15
KEY BUYING CRITERIA, BY END USER
TABLE 16
OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 17
OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY TYPE, 2024–2031 (USD MILLION)
TABLE 18
OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 19
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 20
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 21
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 22
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 23
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 24
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 25
OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 26
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 27
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 29
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 31
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR COMMERCIAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 32
OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 33
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 38
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CLINICAL CONTRACT MANUFACTURING, BY REGION, 2024–2031 (USD MILLION)
TABLE 39
OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 40
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 45
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR CONTRACT DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 46
OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 47
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 52
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 53
OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 54
OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 55
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 60
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 61
OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 62
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 67
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 68
OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 69
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 74
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 75
OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 76
OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION, 2024–2031 (USD MILLION)
TABLE 77
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION, 2024–2031 (USD MILLION)
TABLE 82
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR ASO, BY REGION, 2024–2031 (USD MILLION)
TABLE 83
OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2024–2031 (USD MILLION)
TABLE 84
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2024–2031 (USD MILLION)
TABLE 89
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR SIRNA, BY REGION, 2024–2031 (USD MILLION)
TABLE 90
OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 91
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 96
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 97
OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 98
OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 99
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 104
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 105
OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 106
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 111
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 112
OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 113
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114
EUROPE: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 118
GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 119
OLIGONUCLEOTIDE CDMO MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 122
NORTH AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 123
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 124
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 125
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 126
US: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 127
US: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 128
US: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 129
US: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 130
US: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 131
CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 132
CANADA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 133
CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 134
CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 135
CANADA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 136
EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137
EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 138
EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 139
EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 140
EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 141
EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 142
GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 143
GERMANY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 144
GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 145
GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 146
GERMANY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 147
UK: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 148
UK: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 149
UK: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 150
UK: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 151
UK: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 152
FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 153
FRANCE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 154
FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 155
FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 156
FRANCE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 157
ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 158
ITALY: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 159
ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160
ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 161
ITALY: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 162
SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 163
SPAIN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 164
SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 165
SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 166
SPAIN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 167
REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 168
REST OF EUROPE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 169
REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 170
REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 171
REST OF EUROPE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 172
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 174
ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 175
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 176
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 177
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 178
CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 179
CHINA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 180
CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 181
CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 182
CHINA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 183
JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 184
JAPAN: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 185
JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 186
JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 187
JAPAN: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 188
INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 189
INDIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 190
INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 191
INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 192
INDIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 193
AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 194
AUSTRALIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 195
AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196
AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 197
AUSTRALIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 198
SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 199
SOUTH KOREA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 200
SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 201
SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 202
SOUTH KOREA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 203
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 204
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 205
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 207
REST OF ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 208
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 210
LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 211
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 213
LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 214
BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 215
BRAZIL: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 216
BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 217
BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 218
BRAZIL: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 219
MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 220
MEXICO: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 221
MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222
MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 223
MEXICO: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 224
REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 225
REST OF LATIN AMERICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 226
REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227
REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 228
REST OF LATIN AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 229
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 231
MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 232
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 233
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 234
MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 235
GCC: OLIGONUCLEOTIDE CDMO MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236
GCC: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 237
GCC: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 238
GCC: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239
GCC: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 240
GCC: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 241
SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 242
SAUDI ARABIA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 243
SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 244
SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 245
SAUDI ARABIA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 246
UAE: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 247
UAE: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 248
UAE: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 249
UAE: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 250
UAE: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 251
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 252
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 253
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 254
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 255
REST OF GCC COUNTRIES: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 256
REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 257
REST OF MIDDLE EAST: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 258
REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 259
REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 260
REST OF MIDDLE EAST: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 261
AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 262
AFRICA: OLIGONUCLEOTIDE CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 263
AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 264
AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 265
AFRICA: OLIGONUCLEOTIDE CDMO MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 266
KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023–2026
TABLE 267
OLIGONUCLEOTIDE CDMO MARKET: DEGREE OF COMPETITION
TABLE 268
OLIGONUCLEOTIDE CDMO MARKET: REGIONAL FOOTPRINT
TABLE 269
OLIGONUCLEOTIDE CDMO MARKET: SERVICE TYPE FOOTPRINT
TABLE 270
OLIGONUCLEOTIDE CDMO MARKET: TYPE FOOTPRINT
TABLE 271
OLIGONUCLEOTIDE CDMO MARKET: APPLICATION FOOTPRINT
TABLE 272
DETAILED LIST OF KEY STARTUPS/SMES
TABLE 273
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 274
OLIGONUCLEOTIDE CDMO MARKET: SERVICE LAUNCHES, JANUARY 2023–JULY 2026
TABLE 275
OLIGONUCLEOTIDE CDMO MARKET: DEALS, JANUARY 2023-JULY 2026
TABLE 276
OLIGONUCLEOTIDE CDMO MARKET: EXPANSIONS, JANUARY 2023-JULY 2026
TABLE 277
BACHEM INC.: COMPANY OVERVIEW
TABLE 278
BACHEM INC.: SERVICES OFFERED
TABLE 279
BACHEM INC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026
TABLE 280
BACHEM INC.: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 281
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 282
THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
TABLE 283
THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026
TABLE 284
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 285
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 286
AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED
TABLE 287
AGILENT TECHNOLOGIES, INC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026
TABLE 288
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JULY 2026
TABLE 289
AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 290
WUXI APPTEC: COMPANY OVERVIEW
TABLE 291
WUXI APPTEC: SERVICES OFFERED
TABLE 292
WUXI APPTEC: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 293
MARAVAI LIFESCIENCES: COMPANY OVERVIEW
TABLE 294
MARAVAI LIFESCIENCES: SERVICES OFFERED
TABLE 295
MARAVAI LIFESCIENCES: DEALS, JANUARY 2023–JULY 2026
TABLE 296
LONZA: COMPANY OVERVIEW
TABLE 297
LONZA: SERVICES OFFERED
TABLE 298
LONZA: DEALS, JANUARY 2023–JULY 2026
TABLE 299
LONZA: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 300
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 301
EUROFINS SCIENTIFIC: SERVICES OFFERED
TABLE 302
EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 303
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 304
DANAHER CORPORATION: SERVICES OFFERED
TABLE 305
DANAHER CORPORATION: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 306
DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026
TABLE 307
GENSCRIPT: COMPANY OVERVIEW
TABLE 308
GENSCRIPT: SERVICES OFFERED
TABLE 309
GENSCRIPT: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 310
SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
TABLE 311
SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED
TABLE 312
SYNGENE INTERNATIONAL LIMITED: SERVICE LAUNCHES, JANUARY 2023–JULY 2026
TABLE 313
SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 314
EUROAPI: COMPANY OVERVIEW
TABLE 315
EUROAPI: SERVICES OFFERED
TABLE 316
EUROAPI: DEALS, JANUARY 2023–JULY 2026
TABLE 317
EUROAPI: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 318
AJINOMOTO CO., INC.: COMPANY OVERVIEW
TABLE 319
AJINOMOTO CO., INC.: SERVICES OFFERED
TABLE 320
AJINOMOTO CO., INC.: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 321
AJINOMOTO CO., INC.: DEALS, JANUARY 2023–JULY 2026
TABLE 322
ST PHARM: COMPANY OVERVIEW
TABLE 323
ST PHARM: SERVICES OFFERED
TABLE 324
ST PHARM: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 325
ST PHARM: DEALS, JANUARY 2023–JULY 2026
TABLE 326
KANEKA CORPORATION: COMPANY OVERVIEW
TABLE 327
KANEKA CORPORATION: SERVICES OFFERED
TABLE 328
POLYPEPTIDE GROUP: COMPANY OVERVIEW
TABLE 329
POLYPEPTIDE GROUP: SERVICES OFFERED
TABLE 330
POLYPEPTIDE GROUP: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 331
AURIGENE PHARMACEUTICAL SERVICES LTD.: COMPANY OVERVIEW
TABLE 332
AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED
TABLE 333
BIOSPRING: COMPANY OVERVIEW
TABLE 334
BIOSPRING: SERVICES OFFERED
TABLE 335
BIOSPRING: SERVICE APPROVALS, JANUARY 2023–JULY 2026
TABLE 336
BIOSPRING: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 337
NIPPON SHOKUBAI CO., LTD.: COMPANY OVERVIEW
TABLE 338
NIPPON SHOKUBAI CO., LTD.: SERVICES OFFERED
TABLE 339
NIPPON SHOKUBAI CO., LTD.: SERVICE LAUNCH, JANUARY 2023–JULY 2026
TABLE 340
NIPPON SHOKUBAI CO., LTD.: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 341
LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW
TABLE 342
LGC BIOSEARCH TECHNOLOGIES: SERVICES OFFERED
TABLE 343
LGC BIOSEARCH TECHNOLOGIES: SERVICE LAUNCH, JANUARY 2023–JULY 2026
TABLE 344
LGC BIOSEARCH TECHNOLOGIES: DEALS, JANUARY 2023–JULY 2026
TABLE 345
LGC BIOSEARCH TECHNOLOGIES: EXPANSIONS, JANUARY 2023–JULY 2026
TABLE 346
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 347
RISK ASSESSMENT
FIGURE 1
OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION AND REGIONS CONSIDERED
FIGURE 2
OLIGONUCLEOTIDE CDMO MARKET: YEARS CONSIDERED
FIGURE 4
GLOBAL OLIGONUCLEOTIDE CDMO MARKET, 2024–2031
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET, 2023–2026
FIGURE 6
DISRUPTIONS INFLUENCING GROWTH OF OLIGONUCLEOTIDE CDMO MARKET
FIGURE 7
HIGH-GROWTH SEGMENTS IN OLIGONUCLEOTIDE CDMO MARKET, 2026–2031
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN OLIGONUCLEOTIDE CDMO MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9
INCREASING FOCUS ON PRECISION/PERSONALIZED MEDICINE
FIGURE 10
ANTISENSE OLIGONUCLEOTIDES ACCOUNTED FOR LARGEST SHARE OF OLIGONUCLEOTIDE CDMO MARKET IN NORTH AMERICA IN 2025
FIGURE 11
ASIA PACIFIC TO BE FASTEST-GROWING MARKET IN GLOBAL OLIGONUCLEOTIDE CDMO MARKET DURING FORECAST PERIOD
FIGURE 12
CONTRACT MANUFACTURING TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13
OLIGONUCLEOTIDE CDMO MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14
OLIGONUCLEOTIDE CDMO MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15
VALUE CHAIN ANALYSIS
FIGURE 16
OLIGONUCLEOTIDE CDMO MARKET: ECOSYSTEM ANALYSIS
FIGURE 17
OLIGONUCLEOTIDE CDMO MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 18
INVESTMENT AND FUNDING SCENARIO, 2023–2026 (USD MILLION)
FIGURE 19
IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
FIGURE 20
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY SERVICE TYPE
FIGURE 21
KEY BUYING CRITERIA, BY END USER
FIGURE 22
NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
FIGURE 23
ASIA PACIFIC: OLIGONUCLEOTIDE CDMO MARKET SNAPSHOT
FIGURE 24
REVENUE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, 2021–2025
FIGURE 25
OLIGONUCLEOTIDE CDMO MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025
FIGURE 26
OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2025
FIGURE 27
OLIGONUCLEOTIDE CDMO MARKET: COMPANY FOOTPRINT
FIGURE 28
OLIGONUCLEOTIDE CDMO MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2025
FIGURE 29
BRAND/PRODUCT COMPARATIVE ANALYSIS FOR OLIGONUCLEOTIDE CDMO MARKET, BY COMPANY
FIGURE 30
EV/EBITDA OF KEY VENDORS IN CDMO MARKET
FIGURE 31
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE CDMO MARKET
FIGURE 32
BACHEM INC.: COMPANY SNAPSHOT (2025)
FIGURE 33
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 34
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 35
WUXI APPTEC: COMPANY SNAPSHOT (2025)
FIGURE 36
MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025)
FIGURE 37
LONZA: COMPANY SNAPSHOT (2025)
FIGURE 38
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 39
DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 40
GENSCRIPT: COMPANY SNAPSHOT (2025)
FIGURE 41
SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 42
EUROAPI: COMPANY SNAPSHOT (2025)
FIGURE 43
AJINOMOTO CO., INC.: COMPANY SNAPSHOT (2025)
FIGURE 44
ST PHARM: COMPANY SNAPSHOT (2025)
FIGURE 45
KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 46
POLYPEPTIDE GROUP: COMPANY SNAPSHOT (2025)
FIGURE 47
NIPPON SHOKUBAI CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 48
LGC BIOSEARCH TECHNOLOGIES: COMPANY SNAPSHOT (2024)
FIGURE 49
OLIGONUCLEOTIDE CDMO MARKET: RESEARCH DESIGN
FIGURE 50
OLIGONUCLEOTIDE CDMO MARKET: BREAKDOWN OF PRIMARIES
FIGURE 51
OLIGONUCLEOTIDE CDMO MARKET: INSIGHTS FROM PRIMARIES
FIGURE 52
GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025
FIGURE 53
OLIGONUCLEOTIDE CDMO MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025)
FIGURE 54
ILLUSTRATIVE EXAMPLE OF AGILENT TECHNOLOGIES, INC.: REVENUE ANALYSIS (2025)
FIGURE 55
SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 56
OLIGONUCLEOTIDE CDMO MARKET: CAGR PROJECTIONS
FIGURE 57
OLIGONUCLEOTIDE CDMO MARKET: DATA TRIANGULATION
Growth opportunities and latent adjacency in Oligonucleotide CDMO Market